627 related articles for article (PubMed ID: 24172910)
1. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fatty acid synthase suppresses U-2 OS cell invasion and migration via downregulating the activity of HER2/PI3K/AKT signaling pathway in vitro.
Wang TF; Wang H; Peng AF; Luo QF; Liu ZL; Zhou RP; Gao S; Zhou Y; Chen WZ
Biochem Biophys Res Commun; 2013 Oct; 440(2):229-34. PubMed ID: 24041695
[TBL] [Abstract][Full Text] [Related]
3. Positive feedback regulation between Akt phosphorylation and fatty acid synthase expression in osteosarcoma.
Wang H; Luo QF; Peng AF; Long XH; Wang TF; Liu ZL; Zhang GM; Zhou RP; Gao S; Zhou Y; Chen WZ
Int J Mol Med; 2014 Mar; 33(3):633-9. PubMed ID: 24366211
[TBL] [Abstract][Full Text] [Related]
4. LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.
Zhou Y; Zhu LB; Peng AF; Wang TF; Long XH; Gao S; Zhou RP; Liu ZL
Mol Med Rep; 2015 Feb; 11(2):1352-7. PubMed ID: 25351625
[TBL] [Abstract][Full Text] [Related]
5. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.
Li N; Bu X; Tian X; Wu P; Yang L; Huang P
Nutr Cancer; 2012 Aug; 64(6):864-70. PubMed ID: 22860766
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
8. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
10. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of fatty acid synthase supresses osteosarcoma cell invasion and migration.
Liu ZL; Zhou Y; Luo QF; Hu M; Wang G; Huang SH; Shu Y
Indian J Pathol Microbiol; 2012; 55(2):163-9. PubMed ID: 22771636
[TBL] [Abstract][Full Text] [Related]
13. LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.
Long XH; Zhong ZH; Peng AF; Zhu LB; Wang H; Zhang GM; Liu ZL
Mol Med Rep; 2014 Dec; 10(6):2967-72. PubMed ID: 25310590
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
16. Bisdemethoxycurcumin suppresses human osteosarcoma U‑2 OS cell migration and invasion via affecting the PI3K/Akt/NF‑κB, PI3K/Akt/GSK3β and MAPK signaling pathways
Ma YS; Peng SF; Wu RS; Chueh FS; Huang WW; Chen PY; Kuo CL; Huang AC; Liao CL; Hsia TC
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36222295
[TBL] [Abstract][Full Text] [Related]
17. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K/Akt signaling pathway in vitro.
Liu ZL; Mao JH; Peng AF; Yin QS; Zhou Y; Long XH; Huang SH
Mol Med Rep; 2013 Feb; 7(2):608-12. PubMed ID: 23229760
[TBL] [Abstract][Full Text] [Related]
19. Aclidinium bromide inhibits proliferation of osteosarcoma cells through regulation of PI3K/Akt pathway.
Li ZZ; Wang YL; Yu YH; Xing YL; Ji XF
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):105-112. PubMed ID: 30657552
[TBL] [Abstract][Full Text] [Related]
20. The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells.
Li N; Bu X; Wu P; Wu P; Huang P
Lipids; 2012 Apr; 47(4):403-11. PubMed ID: 22218925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
